WeTrials
Active, not recruiting

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

What is this study?

This study tests a new hormone-blocking drug called giredestrant combined with everolimus to see if it works better than standard hormone therapy plus everolimus. Researchers want to help patients whose estrogen receptor-positive, HER2-negative breast cancer has continued to grow after previous treatments.

Who can participate?

You may be able to join if you have advanced or spreading breast cancer that is estrogen receptor-positive and HER2-negative. Participants must have previously been treated with hormone therapy and CDK4/6 inhibitor drugs, and be willing to provide a blood sample for genetic testing.

What will happen?

Participants will be randomly assigned to receive either the experimental drug giredestrant combined with everolimus or standard hormone therapy combined with everolimus. Your health and the response of your cancer will be closely monitored by the study team throughout the process.

Where and when?

The study has locations in several U.S. states including Alaska, Arizona, and Arkansas. This study is currently active, but it is not looking for new participants right now.

Key Points
  • 1Testing a new combination of giredestrant and everolimus
  • 2For adults with advanced estrogen-positive, HER2-negative breast cancer
  • 3Compares the study treatment against standard hormone therapy options

Related video

ecancer: lead investigator Dr. Erica Mayer on the evERA results from ESMO 2025 (February 2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.